Novartis in US$465m deal with 3B Pharmaceuticals GmbH
Targeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
Syngenta partners with Biotalys
/in News/by Thomas GabrielczykSyngenta has announced to leverage Biotalys AGROBODY technology platform to expand its biocontrol pipeline.
Phialogics AG bags pre-seed financing
/in News/by Thomas GabrielczykPhialogics AG has got a 600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases.
Forbion raises 1.35bn across two funds
/in News/by Thomas GabrielczykEuropean life sciences venture capital company Forbion has raised two oversubscribed funds totalling 1.35 bn.
Ariceum Therapeutics extends Series A to 47.75m
/in News/by Thomas GabrielczykGerman radiopharmaceuticals developer Ariceum Therapeutics has raised a further 22.75m extension of its 25m Series A financing announced in June 2022.
Genmab and argenx combine antibody know-how
/in News/by Thomas GabrielczykGenmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.
Adaptyv Biosytems launches protein engineering foundry
/in News/by Thomas GabrielczykSwiss Adaptyv Biosystems Sàrl has launched two fast-feedback tools that allow cheap, rapid and minaturised validation of AI-designed proteins.
Researchers activate chemotherapeutics by ultrasound
/in News/by Thomas GabrielczykUltrasound that switches cancer drug on could significantly reduce chemotherapy side effects, German researchers found in preclinical studies.
FAO presents food safety assessment on cell-based protein products
/in News/by Thomas GabrielczykAt the beginning of April, the FAO presented a report entitled "Food safety aspects of cell-based food" to establish safety standards for cell-based proteins.
Mosaic Therapeutics closes $28m series A financing
/in News/by Thomas GabrielczykWellcome Sanger Institute spin out Mosaic Therapeutics has closed a $28m series A funding led by Syncona Investment Management Ltd, and Cambridge Innovation Capital.